24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
AFALIEVA 30MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | AFALIEVA 30MG |
|---|---|
| Composition | Afatinib Tablets IP 30mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (28 tab) |
| Country of Origin | India |
AFALIEVA 30MG (Afatinib Tablets IP 30mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
AFALIEVA 30 MG (Afatinib Tablets IP 30 mg) is a prescription targeted anticancer medicine containing Afatinib 30 mg, used primarily for the treatment of specific types of Non-Small Cell Lung Cancer (NSCLC) that carry certain Epidermal Growth Factor Receptor (EGFR) mutations. Afatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs) and works by blocking cancer-promoting signals that help tumors grow and spread.
Lung cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells contain abnormal EGFR mutations that continuously stimulate tumor growth. AFALIEVA 30 MG is specifically designed to target these mutations, helping slow disease progression and improve treatment outcomes.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Afatinib is a targeted therapy that focuses on specific molecular pathways involved in cancer development. This precision-based approach allows healthcare providers to personalize treatment according to the genetic profile of the tumor.
AFALIEVA 30 MG is commonly prescribed for:
Before initiating treatment, oncologists generally recommend molecular testing to confirm the presence of EGFR mutations and determine whether Afatinib is an appropriate treatment option.
Afatinib works by irreversibly blocking multiple members of the ErbB family of receptors, including EGFR, HER2, and HER4. By inhibiting these pathways, it reduces cancer cell growth, limits tumor progression, and promotes cancer cell death.
Manufactured under strict pharmaceutical quality standards, AFALIEVA 30 MG is designed to provide consistent therapeutic performance, quality, and patient safety.
Patients receiving Afatinib therapy typically undergo regular monitoring, including liver function tests, kidney assessments, clinical evaluations, and treatment response assessments to ensure safe and effective therapy.
Due to its proven efficacy in EGFR-positive lung cancer, AFALIEVA 30 MG has become an important component of modern targeted cancer treatment strategies worldwide.
AFALIEVA 30 MG (Afatinib Tablets IP 30 mg) is primarily used in the treatment and management of EGFR mutation-positive lung cancer.
The medicine is widely prescribed for patients with EGFR-positive NSCLC.
Afatinib helps manage advanced-stage lung cancer that cannot be treated surgically.
The medicine may be used when lung cancer has spread to other organs.
Doctors may prescribe Afatinib for patients with locally advanced disease.
In selected cases, Afatinib may be used for squamous cell carcinoma of the lung.
The medicine supports personalized cancer treatment based on genetic testing.
Afatinib helps maintain disease control and delay cancer progression.
Afatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
AFALIEVA works by:
This targeted mechanism helps control cancer growth while minimizing damage to healthy tissues.
Like all medicines, AFALIEVA 30 MG may cause side effects in some patients. The severity and frequency of side effects vary depending on individual patient factors and treatment duration.
Diarrhea is one of the most commonly reported side effects during treatment.
Patients may experience acne-like skin eruptions or rashes.
Skin dryness and irritation may occur.
Painful ulcers or inflammation inside the mouth may develop.
Changes around fingernails and toenails may occur during treatment.
Reduced appetite may affect daily nutritional intake.
Weakness and tiredness are commonly reported.
Some patients may experience mild to moderate nausea.
Weight reduction may occur due to treatment-related effects.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of AFALIEVA 30 MG (Afatinib Tablets IP 30 mg) should always be determined by a qualified oncologist.
Treatment recommendations depend on the diagnosis and mutation profile.
Doctors may adjust dosage according to effectiveness and tolerability.
Dose modifications may be required if significant side effects develop.
Liver and kidney function may influence treatment planning.
Patient-specific factors contribute to dosage decisions.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC).
Afatinib is a targeted anticancer medicine that blocks EGFR and related receptors involved in cancer cell growth.
No. It is a targeted therapy that works differently from conventional chemotherapy medicines.
Genetic testing helps determine whether the cancer contains EGFR mutations that are likely to respond to Afatinib treatment.
Yes. Skin rash, dry skin, and nail changes are among the commonly reported side effects.
Yes. Diarrhea is one of the most common side effects and should be managed under medical supervision.
Yes. Doctors typically recommend routine blood tests, liver assessments, and clinical evaluations throughout therapy.
Yes. This medicine should only be used under the guidance of qualified healthcare professionals experienced in oncology and targeted cancer treatment.